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1. Introduction 
Nicotinic acetylcholine receptors (nAChR) are the archetypes of drug receptors. In 1905, 
John Newport Langley introduced the concept of a receptive substance on the surface of 
skeletal muscle that mediated the action of a drug, such as nicotine and curare (a neurotoxin 
made from a plant) (Langley et al., 1905). He also proposed that these receptive substances 
were different in different species and tissues, and they undergo conformational changes in 
response to the respective drug. Today nAChRs are considered prototypes of receptors that 
function as integral signal transducers. They have the response element and the ion channel 
domain within the same molecular entity as the ligand-binding domain that is activated by 
acetylcholine. In contrast, muscarinic acetylcholine receptors (mAChR) are prototypic G 
protein-coupled receptors. They also sense molecules outside the cell, but they require the G 
proteins to induce cellular responses by coupling to intracellular signalling pathways. More 
important than their historical role, nicotinic receptors continue to be at the forefront of 
science, as they are drug targets for muscle and nerve diseases, such as Alzheimer’s and 
Parkinson’s diseases, Schizophrenia and Myasthenia gravis. Therefore, this receptor family 
serves as an excellent example for demonstrating the suitability of site-directed mutagenesis 
for investigating receptor function and exploring drug action.  
The neurotransmitter acetylcholine binds to the extracellular domain of the nAChR and, 
consequently, opens the receptor-integral membrane channel for Na+, K+ and Ca2+ ions. The 
channel can close in two ways. (1) The acetylcholine dissociates from its extracellular 
binding site, a process that is enhanced by rapid cleavage of the neurotransmitter by the 
acetylcholine esterase in the synaptic cleft. Thus released, the neurotransmitter has only a 
short time to act on nAChRs before the signal is terminated again. (2) The channel closes 
spontaneously despite the presence of transmitter, a process called desensitization. 
Desensitization is a protective mechanism against exposure to acetylcholine and its agonists 
that is too long or too strong. Desensitization thus avoids excessive influx of ions into the 
cell, which can result in impairment of cellular function and cell death. 
Ligand binding to nAChR usually occurs in the submillisecond range. The receptor-integral 
channel is opened only for a few milliseconds and is then closed. Nicotinic receptors are 
therefore extremely fast and efficient signal transducers. They play key roles in such life-
important properties as muscle contraction and brain action. 
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1.1 Structure 
A nAChR is composed of five subunits that form a central pore. The extracellular domain 
contains the binding site for the neurotransmitter acetylcholine (ACh). The four 
transmembrane helices from each subunit make up the integral ion channel. Depicted are 
some of the features described in this section. The C-loop is an important part of the 
acetylcholine binding site. The binding site of the modulating substance galantamine (GAL) 
is situated at another part of the C-loop. A phosphorylation site (P) is important for 
modulating the activity of the receptor. A glycosylation site (G) seems to play a role in 
cobratoxin resistance. Ivermectin and PNU-120596 are other substances that modulate the 
activity of the receptor, but they have different locations (IVE and PNU). The cytoplasmatic 
loop is important for receptor targeting. 
 
Fig. 1. Schematic representation of a nicotinic Acetylcholine Receptor (nAChR) 
The nAChR is assembled from five subunits that are organized around a central pore. 
Seventeen homologous subunits (1 – 10, 1 – 4, ,  and ) are known in vertebrates 
(Zouridakis et al., 2009).  This pool of subunits accounts for the vast number of nACh 
receptor subtypes that exhibit extensive functional diversity with respect to their 
pharmacological profile, spatiotemporal expression patterns and kinetic properties. 
All subunits share the same architectural blueprint, i.e., they consist of a large 
aminoterminal extracellular domain containing the name-giving cysteine loop, followed by 
a transmembrane domain and a small intracellular domain. The transmembrane domain 
consists of four transmembrane regions (TM1 to TM4). TM1, TM2, and TM3 are linked by 
two short loops. A long and highly variable intracellular loop occurs between TM3 and 
TM4. Except for those of the long intracellular loop, the amino acid residues are 
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substantially conserved. This pool of subunits accounts for the vast number of nACh 
receptor subtypes that exhibit extensive functional diversity with respect to their 
pharmacological profile, spatiotemporal expression patterns and kinetic properties. 
1.2 Use of directed mutagenesis in nicotinic acetylcholine receptor research 
Site-directed mutagenesis is a powerful tool to investigate the role of individual amino acids 
within a protein, to understand the function of a given protein or to understand 
pharmacological interactions between the protein and compounds. However, modifying 
individual amino acids or larger parts of a protein with unknown function bears a number 
of risks. (1) The impact of a particular mutation might appear to be subtle, but it could also 
lead to a dysfunctional receptor or to the failure of receptor assembly. (2) A mutation might 
exert an effect on a distant site of the molecule due to conformational changes. This might be 
interpreted wrongly. (3) The mutated protein might adopt new properties that are unrelated 
to the natural protein. Hence, it is advisable always to design a battery of receptor mutants 
or chimeras. It is also important to include similar mutants, either by mutating an amino 
acid to several different amino acids or by creating similar chimeras. If the results of these 
mutants are consistent, the risk of erroneously assigning a wrong function can be reduced. 
Combining mutagenesis studies with other approaches, such as molecular modelling, will 
further substantiate a hypothesis. A number of such cases will be described in Section 2. 
Here, the two major mutant types will be described.  
1.2.1 Single amino acid changes 
Single amino acid changes can be used to investigate the role of amino acids in the binding 
of the natural ligands and drugs. Furthermore, this type of mutagenesis can be applied to 
cases in which computer algorithms have predicted motifs, such as glycosylation or 
phosphorylation sites. Other possible applications are assembly, the targeting of the 
receptor, or the identification of signals for expression. 
A common way to designate a mutant is to use a letter-number-letter scheme. The first letter 
indicates the wild-type amino acid, using the one-letter code (see Table 1 in the chapter by 
Figurski et al. for the amino acid codes); the number refers to the position of the amino acid 
in the protein; and the final letter designates the amino acid that now occupies the position 
of the original amino acid (e.g., T197A refers to a mutant in which threonine at position 197 
was changed to alanine). 
1.2.2 Chimeric receptors 
Chimeric receptors combine parts of different receptors. This type of mutagenesis is useful 
in cases in which, instead of a single amino acid, a whole region is in the centre of interest. 
Examples are functional domains, like the ligand-binding domain or the channel domain, 
and segments critical for protein signalling, sorting or targeting. 
A common way to designate a receptor chimera is to use the names of the receptor types 
and the name of the joining amino acid (e.g., alpha7-V201-5HT3 refers to a chimeric receptor 
with the N-terminal part of the 7 nAChR joined with the C-terminal part of the 5HT3 
receptor at the amino acid valine 201. 
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Fig. 2. Schematic representation of a single subunit each from the 7 receptor, the a7-5HT3 
chimera, and the 5HT3 receptor. The black line denotes the 7 protein; the grey line denotes 
the 5HT3 protein. 
1.3 In vitro systems to test functional properties of mutated receptors 
Electrophysiology is a critical tool for receptor research. This section gives a basic 
introduction to the reader not familiar with this technique. Two methods are commonly 
used: (1) the two-electrode voltage clamp method using Xenopus oocytes and (2) the whole-
cell voltage clamp method amenable for cell lines. 
1. Oocytes from the frog Xenopus laevis produce almost all ion channel receptor types in 
high amounts upon injection of their mRNAs. Since only transient protein expression is 
possible in this system, oocytes can be used only for a short period of a few days. As the 
name suggests, two sharp microelectrodes filled with a high molarity potassium 
chloride solution are pricked into 0.6 to 1 mm oocytes to initiate the recording of 
channel activity. Fortunately an oocyte can be used for several hours. This is enough 
time to allow the study of a series of agonists and antagonists. 
2. The whole-cell patch-clamp technique is the most common electrophysiological method 
used for many mammalian cell lines such as HEK-293, CHO, GH4C1 or PC-12 cells. 
These cells can be easily transfected with nAChR expression vectors. It is possible to 
generate stable cell lines that have integrated the nAChR sequence into the genomic 
DNA. The whole-cell voltage clamp method employs thin pipettes, which enable good 
electrical access to the interior of a cell combined with full external electrical insulation. 
This technique allows measuring small electric currents generated by ion flow through 
a single receptor molecule or through a couple of receptors. The fast gating and 
desensitizing channels require fast and direct drug application methods, such as U-
tubes and Y-tubes. These systems can only be used with the small mammalian cells (10 
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– 20 µm). Heterologously expressed receptors in mammalian cell lines might differ in 
their biophysical and pharmacological characteristics as compared to those analyzed in 
Xenopus laevis oocytes. Therefore, results from the two systems are not always in 
agreement. 
2. Lessons learned from directed mutagenesis 
2.1 Identification of intramolecular signals for nicotinic receptor targeting 
The physiological role of nAChRs depends on their localisation in specific regions of the cell. 
For example, presynaptic receptors regulate the transmitter release from synaptic vesicles 
into the synaptic cleft. Postsynaptic receptors modulate the postsynaptic potential that 
stimulates action potential formation in neurons or at the neuromuscular junction 
(Wonnacott et al., 1997; Albuquerque et al., 2009). The observation of differential expression 
of nAChRs at pre- and postsynaptic sites triggered the search for specific cellular 
localization signals. This section illustrates mutagenesis approaches to investigate receptor 
targeting. 
Chicken ciliary neurons proofed to be an excellent tool to study receptor targeting (Williams 
et al., 1998; Temburni et al., 2000). Ciliary ganglion neurons express two nAChR subtypes: 
(1) 7 nAChRs, for which localisation is restricted to the perisynaptic dendritic membrane 
and (2) heteromeric nAChRs consisting of 3, 5 and 4 subunits, which are expressed 
primarily in postsynaptic membranes (Jacob et al., 1986; Conroy and Berg, 1995). The 3 and 
7 nAChR subunits are highly homologous to each other, with one exception: the long 
cytoplasmatic loop shows great diversity in sequence and length (Lindstrom et al. 1996). It 
also has been shown that this loop is required for the cellular sorting and trafficking 
machinery. Therefore, it might be the candidate domain for subcellular targeting. Chimeric 
7 nAChR subunits were constructed, in which the cytoplasmatic loop was replaced by the 
homologous region of the 3 nAChR subunit. Furthermore, a myc-epitope tag was added at 
the C-terminus to allow detection of the receptor without affecting function. Then the 
chimaeric 7 nAChR subunit with the 3 nAChR cytoplasmatic loop was ectopically 
expressed in chicken ciliary neurons. Indeed this chimeric receptor was targeted to the 
postsynaptic membrane, as shown by antibody staining of the myc-epitope tag. This result 
demonstrates that the cytoplasmatic loop of the 3 nAChR governs the subcellular targeting 
of the receptor. Other endogenous nAChR subunits do not play this role because the nAChR 
subunit does not co-assemble with the 3 nAChR subunit (Conroy and Berg, 1995). In 
addition, 7 nAChR chimeric subunits containing the cytoplasmatic loop of the 5 or 4 
nAChR subunit were designed and expressed. These chimeras were targeted to the 
perisynaptic site (Temburni et al., 2000). This result means that not only the 7 nAChR 
subunit contains signals for perisynaptic localisation, but that the 5 and 4 nAChR 
subunits also do. 
Interestingly, in the case of the 354 heteromer, in which perisynaptic and postsynaptic 
signals are both present, it is the cytoplasmatic loop of the 3 nAChR subunit that 
determines the targeting to the postsynaptic site of ciliary ganglion neurons. Taken together 
the results show that the cytoplasmatic loop contains the cellular localisation signal. 
The next step was to determine the exact signal peptide within the cytoplasmatic loop. 
Before initiating the studies, it was tried to transfer the described approach to hippocampal 
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neurons (Xu et al., 2006). Again the cytoplasmatic loops between the 4 and 7 nAChR 
subunits were swapped and ectopically expressed in various combinations in hippocampal 
neurons. Unfortunately, no surface expression could be detected in cells expressing these 
chimeric nAChR subunits, either alone or in various combinations. It was possible that the 
design of the chimera was too aggressive. Possibly a critical peptide sequence needed to 
enable proper receptor assembly and expression in hippocampal cells was accidentally 
removed.  
Therefore, another mutagenesis strategy was chosen. Swapping internal protein domains 
may affect receptor assembly. Instead model proteins were used. They were left intact, but 
they were tagged with putative signal peptides from the nAChR. Two non-neuronal 
transmembrane proteins were chosen. CD4 and the Interleukin 2 receptor when 
heterologously expressed in neurons are evenly distributed (Gu et al., 2003). It was tested 
whether the intracellular loops of the 4 and 7 nAChR subunits are able to target these 
proteins to specific sites in neurons. When the cytoplasmatic loop of the 7 nAChR was 
fused to the intracellular-oriented C-terminus of CD4, the chimeric protein was only 
detected in the dendrites. In contrast, the homologous 4 nAChR cytoplasmatic loop leads 
to axonal expression. 
In order to narrow down the precise localisation signals in the cytoplasmatic loop of the 
nAChR subunits, the following strategy was chosen. Various overlapping fragments 
covering the loop from its N-terminal region to its C-terminal region were fused to the C-
terminus of the Interleukin-2 receptor. The chimeric receptors were expressed in 
hippocampal neurons. A specific 25-amino acid-fragment (residue positions 30-54) of the 4 
nAChR cytoplasmatic loop targeted the chimera to axons. A 48-residue fragment (positions 
33-80) of the 7 nAChR cytoplasmatic loop targeted the chimaera to dendrites (Xu J. et al. 
2006). 
In a last step, site-directed mutagenesis of specific amino acid residues identified in the 
targeting sequences a leucine motif (DEXXXLLI) in the 4 nAChR cytoplasmatic loop and a 
tyrosine motif (YXXx) in the 7 nAChR loop. 
In conclusion, an iterative approach of chimera design has pin-pointed the precise targeting 
sequence of a receptor. It is important to note that chimera design may destroy receptor 
expression or function. Therefore, it is advisable to generate a set of chimeras and to 
recognize that the change of an expression system may require an adaption of chimera 
design.  
2.2 Confirming computer-based predictions for posttranslational modifications 
Posttranslational modifications are important mechanisms for regulating protein expression 
and protein activity in eukaryotes. Three posttranslational modifications are known for the 
nicotinic acetylcholine receptor family: glycosylation, phosphorylation and palmitoylation 
(Albuquerque et al., 2009). Modern computational algorithms effectively help to identify 
sequence motifs for putative posttranslational modifications. However, experimental 
approaches are needed to confirm that the site is actually used for posttranslational 
modifications and to understand its physiological role. By illustrating the role of 
phosphorylation, this section exemplifies how to combine computational tools with 
mutagenesis strategies.  
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Phosphorylation of α7 nAChR negatively regulates its activity. For example, tyrosine kinase 
inhibition by genistein, a kinase inhibitor, decreases α7 nAChR phosphorylation and, as a 
consequence, strongly increases acetylcholine-evoked currents (Charpantier et al., 2005). 
Therefore, it is interesting to know where and which phosporylation sites are present in the 
protein sequence. Computer analysis predicts two putative phosphorylation sites (tyrosines 
at residues 386 and 442) in the long cytoplasmatic loop between TM3 and TM4 of the human 
α7 nAChR. A site-directed mutagenesis that replaced the tyrosines with alanines (Y386A 
and Y442A) was carried out, and a receptor double mutant with both mutated 
phosphorylation sites was tested in Xenopus oocytes. Indeed the activity of the receptor 
double mutant was increased to an extent comparable to inhibition of the wild-type receptor 
by genistein (a kinase inhibitor). This result confirmed that at least one of the two sites is a 
physiological phosphorylation site. As the receptor double mutant was insensitive to 
genistein, it can also be assumed that there are no additional physiologically relevant 
phosphorylation sites in the protein sequence, which might have been overlooked by the 
computer algorithm. We note that the value of the receptor mutant not only lies in 
confirming the phosphorylation site, but also in establishing a physiological role for this 
posttranslational modification. It is primarily required for the regulation of receptor activity, 
rather than for receptor expression. 
2.3 Receptor chimeras demonstrate the modular domain structure of nAChRs 
As mentioned in the introduction, nAChRs are integral signal transducers in which the 
signalling domain and the response element are within one protein. A key question for 
understanding the molecular design of a receptor family is whether this is achieved through 
a modular architecture with functionally independent and separable elements. 
In 1993 it was impressively demonstrated that domains are interchangeable between 
different ligand-gated ion channels. This was exemplified with chimeras made from the 7 
nAChR and the 5HT3 receptors. The 5HT3 receptor is modulated by the ligand serotonin 
(5HT), permeable for Na+ and K+ ions, but it is blocked by Ca2+ ions. The authors 
constructed recombinant chimeric receptors with the N-terminal part of the 7 type nAChR, 
containing the ligand-binding site, and the C-terminal part of the 5HT3 receptor, containing 
the ion channel domain. They constructed five different chimeras with different junction 
points for the two receptor parts, using conserved residues W173, Y194, V201, L208 and 
P217 (the numbers refer to the residue of the 7 receptor). Four of the five chimeric subunit 
constructs produced properly assembled membrane receptors with an intact extracellular 
ligand-binding domain, as confirmed by radioactive -bungarotoxin-binding assays. 
(bungarotoxin is a competitive inhibitor of acetylcholine and binds with high affinity to 
the acetylcholine-binding site.) Two of the five chimaeras were functional, as shown by the 
two-electrode voltage clamp technique in Xenopus oocytes. One chimera (V201) was able to 
form large acetylcholine-evoked currents; another (Y194) was able to form small currents. 
The V201 chimera was obviously the most interesting chimera and, therefore, was 
investigated thoroughly by electrophysiological methods and compared to the respective 
wild-type receptors.  
First the ligand-binding properties of the chimaera were pharmacologically studied with a 
set of modulators and ligands. The agonists were acetylcholine and nicotine, and the 
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antagonists were -bungarotoxin and curare, both of which have little or no effect on the 
5HT3 receptor. In contrast 5HT, the natural ligand of the 5HT3 receptor, has no effect on the 
7 nAChR receptor. In the Xenopus oocyte system, the chimera responded to these ligands in 
a manner similar to the response of the 7 nAChR wild-type receptor, i.e., acetylcholine 
increased the current; curare inhibited the currents; and 5HT had no effect.  
Second the ion channel properties of the chimera were investigated. 7 type nAChRs and 
5HT3 receptors differ in their sensitivity to external calcium. While 7 type nAChRs currents 
increase with higher calcium concentrations, 5HT3 receptor currents decrease. The 7 
nAChR channel domain is highly conductive for calcium ions, whereas the 5HT3 receptor 
channel domain is blocked by calcium. In addition, external calcium ions have a 
potentiating effect of the acetylcholine action on 7 nAChRs. In Xenopus oocyte studies, the 
7 nACh-V201-5HT3 receptor chimera behaved in a manner similar to the response of the 
5HT3 receptor towards the external calcium concentration. This means that the ion channel 
properties of the 5HT3 receptor are independent of its ligand-binding properties. It appears 
that, by swapping the ligand-binding domains, a 5HT3 receptor can be engineered to 
respond to acetylcholine and other nAChR modulators like a natural nAChR. 
Interestingly, the onset and desensitization kinetics of the current of the chimera is in 
between the rapid kinetics of wild-type 7 nAChR and the slow kinetics of the 5HT3 
receptor. This suggests that not all properties of a receptor can be exchanged by simply 
swapping the ligand-bind domains. The specific kinetic properties of a receptor apparently 
require interplay between different domains.  
In conclusion, computer-based predictions and traditional biochemistry can certainly 
suggest the domain structure of a protein. However, in order to distinguish whether 
domains are functionally independent or just building blocks of a larger functional unit, 
chimeras are invaluable tools.  
2.4 Concatemeric nACh receptors revealed the subunit order of nAChRs 
The principal architecture of heteromeric nAChRs allows for, at least theoretically, 
numerous combinatorial arrangements of the various α, , ,  and  subunit types around 
the central pore. These arrangements could result in many different receptors with different 
properties. Which of the possible arrangements are realized in nature, and what distinct 
properties might they have? For example, it is conceivable that different arrangements of the 
subunits have different acetylcholine-binding properties because the binding site is located 
at the interface of two subunits. 
In neuronal tissue, many different nAChR combinations are usually present. It can be 
difficult to study individual nAChR types. In addition the actual arrangement of the 
subtypes cannot easily be assessed. Directed mutagenesis can be used to force subtypes to 
form specific nAChR arrangements. Thus, it can be a powerful tool for investigating the 
roles of different nAChR arrangements. This section focuses on the 42 type nAChR, 
which is the most abundant form of heteropentameric nACh receptors in the mammalian 
brain.  
A pentameric 42 nAChR could consist of three 4 and two 2 subunits, or vice versa. 
Earlier research using Xenopus laevis oocytes has shown that the use of equal amounts of 4 
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and 2 subunit mRNAs generates an (4)2(2)3 nAChR (i. e., the 4 and 2 subunits are in a 
2:3 stoichiometry, respectively) (Anand et al., 1991; Cooper et al., 1991). In contrast, under 
conditions in which the 4 subunit mRNA was in excess, an (4)3(2)2 nAChR was obtained 
(3:2 stoichiometry) (Zwart and Vijverberg, 1998). The two different 42 nAChRs differ in 
their pharmacological properties. The (4)2(2)3 nAChR is highly sensitive to acetylcholine, 
whereas the (4)3(2)2 nAChR is less sensitive. Since both receptor forms are present in the 
brain (Marks et al., 1999; Gotti et al., 2008), it has been suggested that the ratio of the two 
nAChRs is part of a regulatory mechanism for neuronal cell response to nicotine (Tritto et 
al., 2002; Kim et al., 2003). In addition to their differential sensitivity to acetylcholine and 
nicotine, the two receptor forms differ in other properties, such as desensitization kinetics 
and Ca2+ permeability (Nelson et al., 2003; Zwart et al., 2008; Moroni et al., 2006; Tapia et al., 
2007; Moroni et al., 2008). 
For each stoichiometric nAChR, there exist two possible orders of the subunits. The 
(4)2(2)3 nAChR can be 44222 (1.1) or42422 (1.2). The (4)3(2)2 
nAChR can be 44422 (2.1) or44242 (2.2)Which of the possible 
arrangements are realized and what functional significance is conferred by specific positions 
of each subunit within the receptor complex? Insight into this issue has been gained by 
using a specific type of directed mutagenesis, i.e., concatemers. A concatemer is a long 
synthetic gene that contains smaller genes (e.g., the subunit genes) linked in series. In this 
case, the resulting protein consists of a defined sequence of subunits in which the carboxyl-
terminus of the preceding subunit is covalently linked with the amino-terminus of the 
following subunit (Zhou et al., 2003; Nelson et al, 2003). This technique allows one to enforce 
a predefined subunit order for the receptor. Studies employing this technique with tandem 
and triple concatemers of the  and  subunits showed that only two arrangements were 
functional. For the (4)2(2)3 nAChR, it was the 42422 (1.2)arrangement; and for 
the (4)3(2)2 nAChR, it was the44242 (2.2) arrangement (Carbone et al., 2009). 
Thus, in both receptor forms a triplet of the same subunit was avoided. In summary, the 
mutagenesis studies described improved our understanding of how the subunit types are 
arranged (Zhou et al., 2003; Nelson et al, 2003). 
Recently, the use of a pentameric nAChR concatemer revealed that there exists also at the 
4/4 interface a functional acetylcholine-binding site (Mazzaferro et al., 2011). Originally, 
the acetylcholine-binding sites were thought to be located at the 4/2 subunit interfaces. 
As these interfaces are present in both receptor isoforms, it is unlikely that they account for 
differences in acetylcholine sensitivities. In the new study the authors clearly identified the 
4/4 interface in 44242 receptors as an additional acetylcholine-binding site. 
They used a combined approach of a pentameric nAChR concatemer, chimeric  subunits 
with mutagenesis of loop C and structural modelling to determine that this 4/4 interface 
accounts for isoform-specific characteristics, i.e., for the low acetylcholine sensitivity. In 
conclusion, directed mutagenesis permitted a defining of the order of the nAChR subunits 
and, thus, allowed a determination of the way agonist-binding sites are formed.  
2.5 Cobratoxin 
The α-neurotoxins from snake venoms are potent antagonists of nicotinic acetylcholine 
receptors. In mouse some of them are over ten times more toxic than nicotine (e.g., the LD50 
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of α-cobratoxin from Naja naja in mouse is 0.4 mg/kg versus 7.1 mg/kg for nicotine). 
Despite the high toxicity of the snake toxins, some animals are resistant to α-neurotoxins. 
This is the case for animals that feed on cobras, such as the mongoose, and, of course, the 
snake itself. A substantial effort using directed mutagenesis has been made to characterize 
the interaction between α-neurotoxins and the nicotinic acetylcholine receptors to identify 
the mechanism of this resistance. 
2.5.1 Understanding the cobratoxin – α7 nicotinic acetylcholine receptor interaction 
The binding site of the α7 nAChR is composed of six loops, A to F. In order to identify 
which of these loops interact(s) with α-cobratoxin (α-Cbtx), extensive site-directed 
mutagenesis was carried out to generate 40 receptor mutants (Fruchart-Gaillard et al., 2002). 
The possible role of a given amino acid in a α7 nAChR loop thought to interact with α-Cbtx 
was determined by comparing a mutant receptor with a changed amino acid to the wild-
type receptor using a competition binding assay with radioactive iodide-labelled α-
bungarotoxin.  Only mutations in loops C, D and F reduced the affinity to α-Cbtx. Hence, 
these loops may be critical for α7 nAChR - α-Cbtx interaction. Mutations of loop C at 
residues F186 and Y187 showed the greatest effect. They reduced the affinity by 100- to 200-
fold. It is important to notice that not every mutation at these two positions reduced affinity. 
For example, F186R reduced affinity by a factor of 100; in contrast, F186A reduced affinity 
by a factor of only 4; and F186T, not at all. Hence, when determining a possible role of an 
amino acid by site-directed mutagenesis, amino acid properties may matter (e.g., size or 
charge). It is often important to test several amino acid exchanges for a full understanding. 
Similarly, a site-directed mutagenesis approach was taken to generate 36 toxin mutants. The 
objective was to identify the interaction sites of α-Cbtx with the receptor (Antil-Delbeke et 
al., 2000). This study found loop II and the C-terminal tail of α-Cbtx to interact with α7 
nAChR. 
To determine which amino acid(s) of the receptor interacts with which amino acid(s) of the 
toxin, α7 nAChR receptor mutants were tested with -Cbtx mutants in the competition 
assay. The studies revealed that the amino acid R33 in loop II of α-Cbtx interacts with a 
number of amino acids in loop C of the α7 nAChR, such as Y187, W148, P193, and Y194 
(Fruchart-Gaillard et al., 2002). Another example is the amino acid K35 of α-Cbtx that 
interacts with the amino acids F186 and D163 of the α7 nAChR. 
This information was then used in a computational 3D model to orient α-Cbtx in the binding 
pore of α7 nAChR and to help understand the mechanism of the antagonistic action of α-
Cbtx. How can the large α-Cbtx molecule exert its antagonistic action on a binding site that 
is configured to fit small ligands, such as acetylcholine or nicotine? The docking study 
revealed that only the tip of loop II of the toxin plugs into the cavity between two receptor 
subunits. About 75% of the remaining surface of the toxin stays outside the toxin-receptor 
complex. In this way, α-Cbtx behaves like a small ligand and effectively antagonizes α7 
nAChR. 
2.5.2 Establishing resistance against snake toxin 
A snake is usually resistant to its own venom. Hence, it is interesting to find out whether it 
is resistant from a specific difference in the target molecule of its toxin. In this case, the 
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target molecule is the nicotinic acetylcholine receptor. There are considerable differences in 
the protein sequences of the nAChR ligand-binding domains of snakes (Naja spes) and 
mammals. The differences may suggest the different sensitivities. It is possible to make the 
snake α1 nAChR sensitive to α-Bungarotoxin, a venom of the elapid family. It has been 
shown by site-directed mutagenesis that introducing the mutation N189F, which substitutes 
the asparagine in the snake protein sequence with the phenylalanine in the mouse sequence, 
abolishes resistance (Takacs et al., 2001). This suggests not only that the snake α1 nAChR 
contains a ligand-binding domain for snake toxins, but also that a single amino acid can 
cause sensitivity or resistance. In order to test whether the asparagine indeed confers the 
resistance, a F189N mutation was introduced into the nAChR of the mouse.   Two-electrode 
voltage clamp analysis in Xenopus oocytes showed that this mouse receptor mutant was 
resistant to α-Bungarotoxin. This means that a single amino acid substitution can determine 
sensitivity or resistance to a snake venom.  
Interestingly, N189 is an N-glycosylation site, and it has been postulated that the bulky 
glycosyl residue may prevent the toxin from entering the binding site (Barchan et al., 1992). 
This hypothesis might explain the resistance of the mongoose to snake venoms and the 
sensitivity of mammals. In fact, the mongoose nAChR has an N-glycosylation site at N187, 
whereas other mammals, such as mouse, cat and humans, lack an N-glycosylation site in the 
ligand-binding domain. 
Another resistance mechanism may be deduced from the receptor-toxin interaction, as 
described in the previous section. The F189 residue in the α1 nAChR is analogous to F186 in 
the α7 nAChR. F186 was identified to be critical for the receptor-binding interaction. 
Therefore, it is conceivable that two mechanisms in the snake receptor confer resistance to α-
neurotoxins: (1) disruption of a critical protein-protein interaction and (2) steric hindrance 
via glycosylation. 
2.6 Mapping of the binding sites of allosteric potentiating ligands 
Modulators of ligand-gated ion channels (LGICs) have become therapeutically important 
because, in contrast to traditional agonists or antagonists, these substances change receptor 
activity only in the presence of the natural ligand. This allows a more physiological control 
of a LGIC. This concept has been broadly applied for the treatment of epilepsy. For example, 
benzodiazepines, such as diazepam ("Valium"), present a major class of allosteric 
modulators of the GABAA-receptors. 
Cholinergic neurotransmission is a prominent therapeutic target for the treatment of 
diseases like Alzheimer’s disease. The drug galantamine exerts its therapeutic action by 
allosteric modulation of the nAChRs (Bertrand and Gopalakrishnan, 2007; Maelicke et al., 
2001). Understanding the mechanism of allosteric modulation is therefore important for 
developing novel drugs for treating Alzheimer´s disease (Faghih et al., 2007).  
Today a range of allosteric modulators is known. Synonymously used terms are  “allosteric 
potentiating ligands“ (APL) and “positive allosteric modulators” (PAM). They fall into 
different classes. Galantamine is a representative of the type I class of PAMs (PAM I), which 
enhance nAChR activity by increasing the current without affecting receptor 
desensitization. In contrast, members of the type II class of PAMs (PAM II) increase the 
current of nAChRs, but also reduce their desensitization (Hurst et al., 2005). Hence, a 
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number of studies were directed to the identification of possible different binding sites, 
which would help to explain the mechanistic differences of the two classes. 
2.6.1 PNU-120596 
The group around Neil Millar ran a combined approach to locate the binding site of the 
type II modulator PNU-120596 a well-studied developmental compound. In a first round of 
experiments, they compared the action of PNU-120596 on the 7 nAChR and the 5HT3 
receptor with a set of 7 nACh/5HT3 receptor chimeras (Young et al., 2008). In these 
chimeras, principally the extracellular part of the 7 nAChR was combined with at least the 
first three transmembrane domains from the 5HT3 receptor. PNU-120596 could, of course, 
potentiate 7 nAChR. However it could potentiate neither the original 5HT3 receptor nor 
any of the receptor chimeras. This indicated that the PNU-120596 binding site is located in 
the transmembrane part of the nACh receptor. 
In a second round of mutant receptor designs, the amino acid sequence of the 
transmembrane part of the 7 nAChR was compared with the one from the 5HT3 receptor. 
A number of differences were identified. Amino acids that are not conserved in the 7-
nAChR (which is potentiated by PNU-120596) and the 5HT3 receptor (which is not 
potentiated by PNU-120596) formed the basis for a set of 7 nAChR mutants. Amino acids 
in the nAChR were mutated to the corresponding amino acids of the 5HT3 receptor. As 
expected, some of the mutants were simply not functional, whereas others showed 
responses to PNU-120596 that were similar to that of wild-type nAChR. Five mutants 
having otherwise normal function were less responsive than wild type to the potentiating 
activity of PNU-120596.  Two of them (A225D and M253L) were nearly resistant to PNU-
120596. 
In order to understand why these five amino acids of wild-type nAChR conferred sensitivity 
to PNU-120596 modulation, the authors investigated several computer models of the 
nAChR. It turned out that the five amino acids were part of an intra-subunit cavity. Docking 
simulations revealed that the most favourable docking position of PNU-120596 was at a 
location very near to the locations of the five amino acids. 
Complementary studies using a set of different 7/5HT3 receptor chimeras showed that the 
7 nAChR ion channel domain is essential for the action of PNU-120596 (Bertrand et al., 
2008). This has led to the model that PNU-120596 exerts its function by stabilizing the cavity 
in an agonist-like fashion (Barron et al., 2009).  
In summary, a combined approach of site-directed mutagenesis experiments, molecular 
modelling and docking studies was needed to identify the binding site of PNU-120596.  
2.6.2 Galantamine 
The following studies revealed a totally different location for the binding site of 
galantamine. They offer an explanation of why the mechanisms of action of the two 
allosteric modulating ligands are substantially different.  
The identification of the galantamine binding site on the extracellular domain close to the 
acetylcholine binding site has taken more than a decade. Several different approaches were 
required to finally locate it precisely (Schröder et al., 1994; Ludwig et al., 2010). 
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A first step was the combination of results from earlier studies about an antibody called FK1 
(Schröder et al., 1994; Brejc et al., 2001; Luttmann et al., 2009). An important feature of 
antibody FK1 is its ability to block the potentiating effect of galantamine on the nAChR 
without affecting the response to acetylcholine or agonists. The strategy described in this 
paper helped to identify two stretches (27 and 28 amino acids in length) that contain part of 
the binding site of galantamine. However, the question remained as to which amino acids 
participate in the interaction (Schröder et al., 1994). A protein from a freshwater snail 
assisted in narrowing the range of possible amino acids (Brejc et al., 2001; Smit et al., 2001). 
The freshwater snail Lymnaea stagnalis produces a protein that is homologous to the ligand-
binding domain of nAChRs. It is called Acetyl Choline Binding Protein, and it assembles as 
a homopentamer amenable to X-ray crystallography. A 2.7 Å resolution structure was used 
as a template to model the ligand-binding domains of α7 and α42 nAChRs (Luttmann et 
al., 2009). In these models only a small proportion of the amino acid stretches of the receptor 
lie in a position at the outer surface that would be accessible to the FK1 antibody (Figure 3). 
As both amino acid stretches contribute to the FK1 epitope, it seems highly probable that the 
epitope is located at the junction of the two stretches. 
 
Fig. 3. Surface model of the 7 nAChR ligand-binding domain. Only the ligand-binding 
domain (LBD) is shown. The cell membrane and channel domain would be beneath the LBD. 
Two of the five subunits are shown in light grey, with the other ones depicted in dark grey. 
One molecule of acetylcholine (ACh) is bound. It is almost buried inside the binding site. The 
amino acids in yellow and blue belong to amino acid stretches identified in Schröder et al., 
1994 as contributing to the epitope for the galantamine blocking antibody FK1. Mutation of 
the amino acids T197 and K143 showed no (T197) or reduced (K143) galantamine effect when 
stimulated with acetylcholine. This is in line with the assumption that the galantamine 
binding site is at the junction of these two amino acid stretches. The amino acids T197 and 
K143 are possible binding sites for galantamine (Gal), as predicted by docking studies. 
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These insights led to a hypothetical binding site, which was proven with a set of eight 
different α7 nAChR mutants (Ludwig et al., 2010). All of the mutants were functional, albeit 
two had much lower affinities for acetylcholine and agonists than wild type. Four of the 
mutants, all of which showed a normal response to agonists, had no or a reduced response 
to galantamine. These four mutants were altered in amino acids at the borders of the two 
stretches mentioned above and were adjacent in the 7 nAChR model (Ludwig et al., 2010). 
Docking studies pinpointed two amino acids, threonine 197 and lysine 143, as the 
galantamine binding site (Luttmann et al., 2009). The two amino acids that were replaced in 
the other two mutants were shown to be oriented in a way in which they would be unlikely 
to interact with galantamine directly. 
A mechanistic model to explain how the binding of acetylcholine opens the ion channel 
proposes that the C-loop (Fig. 1) acts as a lever that moves upon binding of acetylcholine. 
Since the galantamine binding site is located at the lower part of the C-loop, it is assumed 
that binding of galantamine enhances the action of this lever. 
2.6.3 Ivermectin 
Ivermectin is a member of the PAM I class of modulators. It has a potentiating action on the 
nAChR activation without affecting the desensitization. Collins and Millar performed an 
approach similar to the one described for PNU-120596 to identify the amino acids that play a 
critical role in the interaction with ivermectin (Collins and Millar, 2010). 
The authors conducted experiments with 7 nAChRs, 5HT3 receptors and the already 
described 7-5HT3 chimeric receptors in Xenopus oocytes. The experiments led to the 
conclusion that the transmembrane domain plays a critical role in the allosteric modulation 
by ivermectin. The results showed that, while ivermectin potentiated the effect of 
acetylcholine on the 7 nAChR, it had no effect on the 5HT3 receptor. In contrast, the 7-
5HT3 chimeric receptor, which contains the ligand-binding domain of the 7 nAChR and the 
ion channel domain of the 5HT3 receptor, was surprisingly inhibited by ivermectin. The 
reason for this unexepected response of the chimeric receptor to ivermectin is not known, 
but it might be that the 5HT3 receptor extracellular domain blocks the access of ivermectin to 
a transmembrane domain binding site that is accessible in the chimeric receptor.  
In subsequent experiments, the authors changed selected amino acids in the α7 nAChR. The 
mutations A225D, Q272V, T456Y, and C459Y almost completely prevented allosteric 
modulation by ivermectin. It is interesting to note that some of these mutants react similarly 
to PNU-120596 and to ivermectin. The A225D and C459Y mutants showed a reduced 
response to both compounds. In contrast, mutations at Q272V and T456V reduced the 
allosteric potentiation of ivermectin, but not of PNU-120596. This suggests that the amino 
acids responsible for the allosteric potentiating action of ivermectin partially overlap the 
ones responsible for the action of PNU-120596. 
2.6.4 Conclusion 
Section 2.6 describes the use of directed mutagenesis for the identification and 
investigation of the binding sites of the three nAChR modulators PNU-120596, 
galantamine and ivermectin. Galantamine and ivermectin are classified as PAM I 
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modulators, while PNU-120596 is a PAM II class allosteric modulator, based on 
electrophysiological properties. However, the binding site of galantamine is on the 
extracellular ligand-binding domain, while ivermectin and PNU-120596 bind to the 
channel domain of the receptor. Apparently similar electrophysiological properties do not 
reflect similar binding sites. 
3. Concluding remarks 
This chapter has highlighted milestones of the directed mutagenesis research performed on 
nAChRs. It includes research about receptor targeting, the modular domain architecture, 
the order of the heteromeric subunit assembly, the mechanism of toxin resistance and the 
receptor interaction with modulatory ligands. Future research will continue to investigate 
the nicotinic receptor family and its role in diseases, such as Alzheimer’s or Parkinson’s. 
The interaction between α7 nAChR and -amyloid is just one of the many urgent questions 
that need to be resolved (Tong et al., 2011). Directed mutagenesis will remain one of the 
most powerful tools on the journey towards the full understanding of this molecular 
machine. 
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